Eplerenone Patent Expiration
Eplerenone is Used for treating hypertension, heart failure, and conditions related to hyperaldosteronism, often in combination with an ACE inhibitor. It was first introduced by Upjohn Us 2 Llc
Eplerenone Patents
Given below is the list of patents protecting Eplerenone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inspra |
US6863902 (Pediatric) | Immediate release eplerenone compositions |
Oct 10, 2020
(Expired) | Upjohn |
| Inspra |
US6410054 (Pediatric) | Immediate release eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6495165 (Pediatric) | Eplerenone compositions having improved bioavailability |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6534093 (Pediatric) | Immediate release eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6558707 (Pediatric) | Immediate release eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US7157101 (Pediatric) | Micronized eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6410524 (Pediatric) | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
May 05, 2020
(Expired) | Upjohn |
| Inspra |
US6747020 (Pediatric) | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
May 05, 2020
(Expired) | Upjohn |
| Inspra | US6863902 | Immediate release eplerenone compositions |
Apr 10, 2020
(Expired) | Upjohn |
| Inspra | US6410054 | Immediate release eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6495165 | Eplerenone compositions having improved bioavailability |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6534093 | Immediate release eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6558707 | Immediate release eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US7157101 | Micronized eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6410524 | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
Nov 05, 2019
(Expired) | Upjohn |
| Inspra | US6747020 | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
Nov 05, 2019
(Expired) | Upjohn |
Eplerenone's Family Patents
Explore Our Curated Drug Screens
Eplerenone Generic API Manufacturers
Several generic applications have been filed for Eplerenone. The first generic version for Eplerenone was by Chartwell Rx Sciences Llc and was approved on Jul 30, 2008. And the latest generic version is by Annora Pharma Private Ltd and was approved on Jun 2, 2023.
Given below is the list of companies who have filed for Eplerenone generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG | tablet | Prescription | ORAL | AB | Jul 13, 2017 |
| 25MG | tablet | Prescription | ORAL | AB | Jul 13, 2017 |
2. ANNORA PHARMA
Annora Pharma Private Ltd has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Annora Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Prescription | ORAL | AB | Jun 2, 2023 |
| 50MG | tablet | Prescription | ORAL | AB | Jun 2, 2023 |
Manufacturing Plant Locations New
Annora Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Annora Pharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
3. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Prescription | ORAL | AB | Sep 14, 2018 |
| 50MG | tablet | Prescription | ORAL | AB | Sep 14, 2018 |
Manufacturing Plant Locations New
Breckenridge's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Breckenridge as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
4. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Prescription | ORAL | AB | Jul 30, 2008 |
| 50MG | tablet | Prescription | ORAL | AB | Jul 30, 2008 |
5. PRASCO
Prasco Llc Dba Prasco Laboratories has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Prasco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Discontinued | ORAL | N/A | Feb 2, 2017 |
| 50MG | tablet | Discontinued | ORAL | N/A | Feb 2, 2017 |
Manufacturing Plant Locations New
Prasco's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Prasco as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
6. RISING
Rising Pharma Holdings Inc has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Prescription | ORAL | AB | Mar 23, 2022 |
| 50MG | tablet | Prescription | ORAL | AB | Mar 23, 2022 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||
| Mexico |
| |||||||||||||||||||
| India |
| |||||||||||||||||||
7. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Prescription | ORAL | AB | Aug 1, 2008 |
| 50MG | tablet | Prescription | ORAL | AB | Aug 1, 2008 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
8. SLATE RUN PHARMA
Slate Run Pharmaceuticals Llc has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Slate Run Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Prescription | ORAL | AB | Aug 10, 2020 |
| 50MG | tablet | Prescription | ORAL | AB | Aug 10, 2020 |
9. WESTMINSTER PHARMS
Westminster Pharmaceuticals Llc has filed for 2 different strengths of generic version for Eplerenone. Given below are the details of the strengths of this generic introduced by Westminster Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG | tablet | Prescription | ORAL | AB | Oct 25, 2021 |
| 50MG | tablet | Prescription | ORAL | AB | Oct 25, 2021 |